Polypharmacy among people diagnosed with colorectal cancer in Australia: a population-based cohort study
Polypharmacy is highly prevalent among Australians with CRC. For those treated with curative intent, higher polypharmacy rates are concerning, indicating excess morbidity and impaired quality of life among survivors cured of cancer but who may continue to experience poorer health than the general population.
Authors
- Mónica Tang (ORCID: https://orcid.org/0000-0003-0075-2176)
- Sallie‐Anne Pearson (ORCID: https://orcid.org/0000-0001-7137-6855)
- Benjamin Daniels (ORCID: https://orcid.org/0000-0001-8617-6055)
- Maria Aslam (ORCID: https://orcid.org/0000-0001-8863-2181)
Institutions
- Population Council (IN)
- Prince of Wales Hospital (AU)
- Hunter New England Local Health District (AU)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1093/oncolo/oyaf380
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Australian Government
- Cancer Institute NSW
- University of New South Wales
- Department of Health and Aged Care, Australian Government
- NSW Ministry of Health
- Medical Research Council
- National Health and Medical Research Council